Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs STMicroelectronics NV (STM) Price & Performance

AbCellera Biologics IncTrade
STMicroelectronics NVTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs STMicroelectronics NV — how do they compare? AbCellera Biologics Inc trades at $9.04 (market cap $2.85B), while STMicroelectronics NV trades at $55.44 (market cap $49.31B). The key difference: STMicroelectronics NV is far larger — about 17.3× AbCellera Biologics Inc's market cap, and STMicroelectronics NV pays a 0.66% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.

ABCLSTM
Market Cap
$2.85B$49.31B
Sector
HealthFinancials
52-Week High
$9.76$79.91
52-Week Low
$2.78$21.20
Enterprise Value
$2.45B$47.30B
Dividend Yield
0.66%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.

The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.

STMicroelectronics NV

STM trades at $56.10, up 5.29% with a bullish technical signal despite recent earnings misses. The stock shows mixed fundamentals with a high P/E of 110 but improving revenue outlook to $13.1B for 2026. Recent news highlights AI data center growth potential targeting $2B by 2027, though Q3 2026 revenue guidance missed estimates causing volatility.

Analyst consensus remains positive with $74.63 price target (51.72% buy ratings), but execution risks in AI expansion and margin pressure from Power & Discrete segments warrant caution. The stock offers growth exposure to semiconductor recovery with balanced risk-reward near current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About STMicroelectronics NV

A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.

Read more on STM